240 related articles for article (PubMed ID: 21718264)
1. Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events?
Paquette A; Gou P; Tannenbaum C
J Am Geriatr Soc; 2011 Jul; 59(7):1332-9. PubMed ID: 21718264
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
Callegari E; Malhotra B; Bungay PJ; Webster R; Fenner KS; Kempshall S; LaPerle JL; Michel MC; Kay GG
Br J Clin Pharmacol; 2011 Aug; 72(2):235-46. PubMed ID: 21392072
[TBL] [Abstract][Full Text] [Related]
3. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.
Chapple CR; Khullar V; Gabriel Z; Muston D; Bitoun CE; Weinstein D
Eur Urol; 2008 Sep; 54(3):543-62. PubMed ID: 18599186
[TBL] [Abstract][Full Text] [Related]
4. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
Wagg A; Compion G; Fahey A; Siddiqui E
BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
[TBL] [Abstract][Full Text] [Related]
5. Effect of Antimuscarinic Drugs on Cognitive Functions in the Management of Overactive Bladder in Elderly.
Rangganata E; Widia F; Rahardjo HE
Acta Med Indones; 2020 Jul; 52(3):255-263. PubMed ID: 33020336
[TBL] [Abstract][Full Text] [Related]
6. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder.
Yamada S; Ito Y; Nishijima S; Kadekawa K; Sugaya K
Pharmacol Ther; 2018 Sep; 189():130-148. PubMed ID: 29709423
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of neurocognitive dysfunction with overactive bladder medications.
Duong V; Iwamoto A; Pennycuff J; Kudish B; Iglesia C
Int Urogynecol J; 2021 Oct; 32(10):2693-2702. PubMed ID: 34213600
[TBL] [Abstract][Full Text] [Related]
8. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin.
Kay GG; Ebinger U
Int J Clin Pract; 2008 Nov; 62(11):1792-800. PubMed ID: 18699842
[TBL] [Abstract][Full Text] [Related]
9. Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: a network meta-analysis.
Yang N; Wu Q; Xu F; Zhang X
J Int Med Res; 2021 Sep; 49(9):3000605211042994. PubMed ID: 34510960
[TBL] [Abstract][Full Text] [Related]
10. Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis.
Vouri SM; Kebodeaux CD; Stranges PM; Teshome BF
Arch Gerontol Geriatr; 2017; 69():77-96. PubMed ID: 27889591
[TBL] [Abstract][Full Text] [Related]
11. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach.
Kessler TM; Bachmann LM; Minder C; Löhrer D; Umbehr M; Schünemann HJ; Kessels AG
PLoS One; 2011 Feb; 6(2):e16718. PubMed ID: 21373193
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Cardozo L; Thorpe A; Warner J; Sidhu M
BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
[TBL] [Abstract][Full Text] [Related]
13. Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients.
Pagoria D; O'Connor RC; Guralnick ML
Curr Urol Rep; 2011 Oct; 12(5):351-7. PubMed ID: 21607875
[TBL] [Abstract][Full Text] [Related]
14. Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
Cetinel B; Onal B; Gultekin MH; Guzelsoy M; Turegun FA; Dincer M
Int Urol Nephrol; 2019 Mar; 51(3):417-424. PubMed ID: 30725387
[TBL] [Abstract][Full Text] [Related]
15. A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older.
Wagg A; Arumi D; Herschorn S; Angulo Cuesta J; Haab F; Ntanios F; Carlsson M; Oelke M
Age Ageing; 2017 Jul; 46(4):620-626. PubMed ID: 28057620
[TBL] [Abstract][Full Text] [Related]
16. Trospium chloride treatment of overactive bladder.
Biastre K; Burnakis T
Ann Pharmacother; 2009 Feb; 43(2):283-95. PubMed ID: 19193592
[TBL] [Abstract][Full Text] [Related]
17. In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment.
Maruyama S; Tsukada H; Nishiyama S; Kakiuchi T; Fukumoto D; Oku N; Yamada S
J Pharmacol Exp Ther; 2008 Jun; 325(3):774-81. PubMed ID: 18326811
[TBL] [Abstract][Full Text] [Related]
18. Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study.
Arana A; Margulis AV; McQuay LJ; Ziemiecki R; Bartsch JL; Rothman KJ; Franks B; D'Silva M; Appenteng K; Varas-Lorenzo C; Perez-Gutthann S
Pharmacotherapy; 2018 Jun; 38(6):628-637. PubMed ID: 29723926
[TBL] [Abstract][Full Text] [Related]
19. Treatments for overactive bladder: focus on pharmacotherapy.
Geoffrion R;
J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses.
Buser N; Ivic S; Kessler TM; Kessels AG; Bachmann LM
Eur Urol; 2012 Dec; 62(6):1040-60. PubMed ID: 22999811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
